4.2 Article

Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis

Journal

JOURNAL OF NEUROIMAGING
Volume 33, Issue 1, Pages 85-93

Publisher

WILEY
DOI: 10.1111/jon.13057

Keywords

gadolinium-based contrast agent; magnetic resonance imaging; multiple sclerosis

Ask authors/readers for more resources

The clinical correlation between gadolinium-based contrast agents (GBCAs) and multiple sclerosis (MS) has not been well studied. This study investigated the association between the cumulative number of GBCA exposures and self-reported disability and performance measures in MS patients. The results showed weak associations between contrast ratio in globus pallidus and the measures, but the associations disappeared after adjusting for covariates. Linear GBCA administrations were associated with better outcomes in terms of PDDS, while macrocyclic GBCA administrations were associated with better outcomes in terms of MDT. No detrimental effects were observed between GBCA exposure and disability or performance measures.
Background and Purpose The clinical correlation of gadolinium-based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self-reported disability and performance measures. Methods A cohort of MS patients was analyzed in this retrospective observational study. The main outcome was the association between the cumulative number of GBCA exposures (linear or macrocyclic GBCA), Patient-Determined Disease Steps (PDDS), and measures of physical and cognitive performance (walking speed test, manual dexterity test [MDT], and processing speed test [PST]). The analysis was performed first cross-sectionally and then longitudinally. Results The cross-sectional data included 1059 MS patients with a mean age of 44.0 years (standard deviation = 11.2). While the contrast ratio in globus pallidus weakly correlated with PDDS, MDT, and PST in a univariate correlational analysis (coefficients, 95% confidence interval [CI] = 0.11 [0.04, 0.18], 0.15 [0.08, 0.21], and -0.16 [-0.10, -0.23], respectively), the associations disappeared after covariate adjustment. A significant association was found between number of linear GBCA administrations and PDDS (coefficient [CI] = -0.131 [-0.196, -0.067]), and MDT associated with macrocyclic GBCA administrations (-0.385 [-0.616, -0.154]), but their signs indicated better outcomes in patients with greater GBCA exposures. The longitudinal data showed no significant detrimental effect of macrocyclic GBCA exposures. Conclusion No detrimental effects were observed between GBCA exposure and self-reported disability and standardized objective measures of physical and cognitive performance. While several weak associations were found, they indicated benefit on these measures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available